Clinical economic assessment of the use of pazopanib in the therapy of disseminated kidney cancer
Objective: to carry out a pharmacoeconomic analysis of using tyrosine kinase inhibitors for the targeted therapy of disseminated renal cell carcinoma.Materials and methods. The data on the efficacy and safety of therapy with tyrosine kinase inhibitors were obtained from the analysis of the results o...
Main Authors: | S. K. Zyryanov, M. Yu. Frolov, I. N. Dyakov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2016-05-01
|
Series: | Onkourologiâ |
Subjects: | |
Online Access: | https://oncourology.abvpress.ru/oncur/article/view/562 |
Similar Items
-
Clinical and economic analysis of the 1st and 2nd target lines
by: I. N. D’yakov, et al.
Published: (2016-12-01) -
Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
by: Fiala O, et al.
Published: (2021-05-01) -
Pazopanib as first-line therapy for patients with metastatic kidney cancer
by: B. Ya. Alekseev, et al.
Published: (2018-07-01) -
Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis
by: Huan Deng, et al.
Published: (2019-05-01) -
Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
by: Jun Guo, et al.
Published: (2018-05-01)